Abstract
Purpose of review: Following the evidence that T-cell responses are crucial in the control of HIV-1 infection, vaccines targeting T-cell responses were tested in recent clinical trials. However, these vaccines showed a lack of efficacy. This review attempts to define the qualitative and quantitative features that are desirable for T-cell-induced responses by vaccines. We also describe strategies that could lead to achievement of this goal. Recent Findings: Using the yellow fever vaccine as a benchmark of an efficient vaccine, recent studies identified factors of immune protection and more importantly innate immune pathways needed for the establishment of long-term protective adaptive immunity. Summary: To prevent or control HIV-1 infection, a vaccine must induce efficient and persistent antigen-specific T cells endowed with mucosal homing capacity. Such cells should have the capability to counteract HIV-1 diversity and its rapid spread from the initial site of infection. To achieve this goal, the activation of a diversified innate immune response is critical. New systems biology approaches will provide more precise correlates of immune protection that will pave the way for new approaches in T-cell-based vaccines.
Original language | English (US) |
---|---|
Pages (from-to) | 368-376 |
Number of pages | 9 |
Journal | Current Opinion in HIV and AIDS |
Volume | 5 |
Issue number | 5 |
DOIs | |
State | Published - Sep 2010 |
Externally published | Yes |
Keywords
- HIV-1 vaccine
- dendritic cell targeting
- protective T cell
ASJC Scopus subject areas
- Immunology
- Hematology
- Oncology
- Oncology(nursing)
- Infectious Diseases
- Virology